Actively Recruiting
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
Led by University Health Network, Toronto · Updated on 2024-06-18
100
Participants Needed
1
Research Sites
415 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer. Participants will receive external beam radiotherapy as a moderately hypofractionated boost to the prostate with pelvic radiation therapy. Androgen deprivation therapy will be prescribed at the discretion of the treating physician as per standard of care.
CONDITIONS
Official Title
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Able to provide informed consent
- Histologic diagnosis of prostate adenocarcinoma
- ECOG performance status 0-1
- High-risk localized disease by NCCN criteria (>cT3, Grade group >4, or PSA >20 ng/mL) or clinical N1 disease
- Clinical M0 by conventional imaging (CT and bone scan) and/or molecular imaging (PSMA-PET)
You will not qualify if you...
- Prior pelvic radiotherapy
- Contraindications to radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Center
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
R
Rachel Glicksman, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here